• Tue. Jul 23rd, 2024

Lara Goldstein

  • Home
  • Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results

Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results

[ad_1] Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare IXHL announced that its Phase 2 clinical trial assessing proprietary psilocybin-assisted psychotherapy for Generalized Anxiety Disorder (GAD)…

Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment

[ad_1] Life sciences biotech company Cybin Inc. CYBN announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its…

Cathie Wood Reacts To Atai’s Drastic Stock Plunge After Doomed Clinical Study Results – Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI)

[ad_1] After atai Life Sciences ATAI shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psychedelics biotech’s stocks plummeted. The closing stock price…

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products – GH Research (NASDAQ:GHRS), PharmaTher Holdings (OTC:PHRRF)

[ad_1] Two psychedelics companies have shared their updates and key milestones to be reached this 2023. The 5-MeO-DMT Business Clinical-stage biopharma company GH Research PLC GHRS has received initial regulatory…

Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans – Mind Medicine (NASDAQ:MNMD), Cybin (AMEX:CYBN)

[ad_1] It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year. Cybin’s Programs For…